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Abstract: In primates, adequate growth of the fetus depends on the development of the 
  uteroplacental unit. On the fetal side, this is achieved by the creation of the vascular network 
of the placenta. On the maternal side, the transformation of the spiral arteries into saccular 
nonreactive vessels by the trophoblast provides high blood flow to the intervillous space. 
Apart from the changes in the uterine arteries, the mother expands her plasma volume – at the 
expense of stimulating the renin-angiotensin-aldosterone system – and her cardiac output. In 
the maintaining of normotension in the face of an increased cardiac output and plasma volume, 
the renin-angiotensin-aldosterone system requires an enhanced vasodilator synthesis. Finally, 
in the late stages of pregnancy, a normal endothelial function is required to provide an ample 
margin to the activation provoked by deportation of syncytiotrophoblast fragments/factors to 
the maternal circulation. These four adaptative processes require various interrelated vasodilator 
systems. Deficient adaptations cause isolated or proteinuric arterial hypertension, intrauterine 
growth restriction, preterm delivery, and stillbirths, among others. Moreover, a normal or a 
defective adaptation to pregnancy influences maternal cardiovascular health in later life, as 
evidenced by various studies, most of them epidemiological; thus, pregnancy is now considered 
a stress test to the maternal cardiovascular system. Because of this, women planning to become 
pregnant should be screened for clinical and biochemical cardiovascular risks. Inversely, women 
presenting with hypertension in pregnancy should be thoroughly studied to detect and correct 
cardiovascular risks. The incorporation of the predictive value of a hypertensive pregnancy 
should help reduce cardiovascular disease in women.
Keywords: renin-angiotensin-aldosterone system, prostanoids, kallikrein-kinin system, RAS, 
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Introduction
In primates, adequate growth of the fetus depends on the morphological and functional 
development of the uteroplacental unit. On the fetal side, this is achieved by the cre-
ation of the vascular network of the placenta from hemangioblasts.1 On the maternal 
side, this is achieved by (1) the transformation of the uterine arteries by extravillous 
trophoblasts that destroy their smooth muscle layer, change their tubular conforma-
tion into a saccular one, and make them nonreactive to vasomotor stimuli;2,3 and (2) 
the elevation of the mother’s plasma volume and cardiac output to bathe the placental 
villi with increasing fractions of the cardiac output.4,5
The expansion of plasma volume is due to the renin-angiotensin (Ang)-aldosterone 
system; plasma renin activity (PRA) and aldosterone levels increase progressively 
to attain values 7–8-fold higher than basal ones. In this context, the normotension of 
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approximately 90% of pregnant women, the reduction of 
blood pressure in the second trimester, and the decreased 
sensitivity to endogenous Ang II infusion6 are difficult to 
understand, unless we invoke a potent vasodilatory response. 
The functional relevance of vasodilators to increase maternal 
vascular compliance in pregnancy is supported by the asso-
ciation of preeclampsia and intrauterine growth retardation to 
a reduced plasma volume that precedes the clinical expression 
of the syndrome.5,7 Moreover, in preeclampsia, PRA and Ang 
II levels are reduced,8 and the increase of vascular reactivity 
to Ang II contrasts with the decreased sensitivity observed 
in normal pregnancy.6
Convinced that an orchestrated network of vasodilator 
systems participates in the systemic and local changes of 
pregnancy, the authors of this paper have strived to under-
stand their temporal profiles, localization, and potential roles. 
The following analysis will include a brief description of 
the main vasodilator agents/factors, the description of their 
systemic and local expression in human normal pregnancy 
and preeclampsia, and lastly an analysis of the implications 
of a defective adaptation over late cardiovascular morbi-
mortality. (For a review that includes animal models, see 
Valdés et al.)9
Vasodilator factors and their  
systemic response in normotensive  
and preeclamptic pregnancy
Prostanoids
Prostanoids are derived from arachidonic acid, which is 
mobilized from the cell membrane by phospholipase A2 
and is metabolized by cyclooxygenases (COXs) (constitu-
tive [COX-1] and inducible [COX-2]) into vasodilatory or 
vasoconstrictor prostaglandins (PGs) (PGE2/prostacyclin 
[PGI2] and PGF2α/thromboxane [TXA] respectively). PGI2, 
the main vasodilatory and antiaggregating PG, is predomi-
nantly synthesized by the endothelium10 and represents the 
first vasoactive factor studied in this condition.11,12
For more than two decades, there has been evidence that 
the metabolites of PGI2 rise progressively to achieve a fivefold 
increment at term. Since this increment is not associated to 
increased TXA, the balance favors vasodilatation.11 Women 
with severe preeclampsia have a reduced excretion of PGI2 
metabolites by weeks 13–16 of pregnancy, while TXA remains 
stable up to week 21, to rise later causing a predominance 
of vasoconstriction and platelet aggregation. This imbalance 
could contribute to the main characteristics of preeclampsia, as 
hypertension, platelet aggregation, and reduced   uteroplacental 
blood flow. Due to the disturbed PGI2/TXA balance several 
trials have tested low dose aspirin administration in women at 
risk of preeclampsia, with the intention of reducing synthesis 
of TXA in platelets, while that of endothelial PGI2 remains 
intact. However, the incidence of preeclampsia has only 
been reduced modestly (12% in the Collaborative Low-dose 
Aspirin Study in Pregnancy)13, suggesting that there is more 
to preeclampsia than an increment of TXA.
Nitric oxide (NO)
NO, a potent vasodilator, is derived from the transformation 
of L-arginine into NO and citruline by NO synthase (NOS). 
The three cognate forms of NOS are the constitutive endothe-
lial (eNOS) and neuronal (nNOS) forms, and the inducible 
(iNOS) form.14
In pregnant rats, NO synthesis increases, as demonstrated 
by plasma levels, urinary nitrites/nitrates, and cyclic guanos-
ine monophosphate, second messenger of NO;15 moreover, 
the blockade of NO synthesis induces marked preeclampsia-
like effects.16,17 In human pregnancy, changes in the urinary 
excretion of nitrites/nitrates have been discordant, and this 
has been attributed to different content of these metabolites 
in the diet, and to a poor equivalence with NO production. 
However, elevated asymmetric dimethylarginine (ADMA), 
an endogenous inhibitor of NOS is associated to endothelial 
dysfunction, alterations of the uterine artery blood flow, and 
later development of preeclampsia.18
Kallikrein-kinin system (KKS)
The KKS system includes a couple of serine proteases: 
tissue and plasma kallikrein, which generate kallidin 
and bradykinin from low and high molecular kininogen 
respectively. The effects of kinins are mediated by brady-
kinin receptors (B1R and B2R), of which the B2R induces 
  vasodilatation and increased vascular permeability and 
platelet antiaggregation.19
The authors of this paper initially postulated that in preg-
nancy the KKS represented a counterpart to the vasoconstric-
tor renin-Ang system. However, the nadir attained by urinary 
kallikrein excretion in normal pregnancy between 8 and 12 
weeks20 precedes the highest levels of vasoconstrictors. In 
hypertensive pregnancies, urinary kallikrein is reduced, and 
low values are a good predictor of preeclampsia.8,21,22
Vasodilator components  
of the renin-Ang system (RAS)
The RAS has traditionally been considered the paradigmatic 
vasoconstrictor system.23 More recently, various   vasodilator 
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pathways have been described within the RAS. One is 
represented by Ang-(1–7), the Mas receptor and the Ang 
converting enzyme-2 (ACE2);24 another by the stimulation 
of the receptor 2 of Ang II (AT-2-R) causes vasodilata-
tion, antiproliferation, antifibrosis, and antiangiogenesis by 
activating eNOS and kinins;25–27 and lastly, by Ang-(3–8) or 
Ang IV, which provokes hypertrophy, vasodilatation, and 
vascular inflammation.28
Generation of Ang-(1–7) is increased in normotensive 
human gestation as demonstrated by increasing urinary 
excretion starting from 12 to 14 weeks, and by the elevation 
of plasma levels that result in late-pregnancy values 1.5-fold 
greater than those of nonpregnant women.29,30 In preec-
lampsia, the circulating levels of Ang-(1–7) are reduced, 
a circulating agonistic antibody for the vasoconstrictor 
AT-1-R appears,31 and heterodimers of the AT-1-R−B2R 
receptors are increased in platelets and omental vessels;32 
these heterodimers increase the vasoconstrictor effect of 
Ang II and reduce the vasodilatation of bradykinin. More 
recently, Zhou and collaborators have shown that oxidation 
of angiotensinogen, which has been observed in preeclamp-
sia, renders this substrate more effective at liberating Ang 
by renin activity.33
Vasodilator role of vascular endothelial  
growth factor (VEGF)
VEGF, considered the most potent angiogenic stimulus, 
increases vascular permeability, cell migration, synthesis 
of metalloproteinases, and most importantly for this review, 
vasodilatation through NO and PGI2.34–36 These effects are 
exerted through its receptors: VEGF receptor (VEGF-R)1 or 
fms-like tyrosine kinase (FLT)-1, and VEGF-R2 or kinase 
domain receptor (KDR).37,38
In women submitted to in-vitro fertilization, circulating 
levels of VEGF increase approximately 30 days after embryo 
transfer,39 and continue to increase up to weeks 34–36.40 
Placental lobes liberate VEGF to the fetal and the maternal 
compartment, with a predominance to the latter.41
The binding of VEGF to its receptors is reduced by a 
soluble form (sFLT-1) generated by alternative splicing of 
FLT-1. The minimal circulating levels in the nonpregnant 
condition rise in pregnancy and are extremely elevated 
in preeclampsia, probably derived from the ischemic 
placenta.42,43 Mice transfected with the gene coding sFLT-1 
present a preeclampsia-like syndrome in the absence of 
pregnancy.42
The studies described above support the participation 
of several interrelated vasodilator systems in the maternal 
hemodynamic changes of pregnancy as a partially   redundant 
network (Figure 1). It is highly likely that this network 
provides chained relay mechanisms in order to exert per-
manent vasodilatation along the changing hormonal milieu 
of pregnancy.
Expression of vasodilator factors in the 
uteroplacental interface
Since the vasodilator factors display paracrine/autocrine 
effects, their expression in reproductive human tissues is cru-
cial to understand their participation in trophoblast invasion 
and in the development and maintenance of uteroplacental 
circulation.
Prostanoids
COX-1 is expressed in trophoblasts, endothelial cells, 
macrophages, smooth muscle, and decidual cells. COX-2 
is expressed in macrophages, trophoblasts, fibroblasts, 
smooth muscle, and endothelial cells, and the expression of 
its mRNA does not differ between normal and preeclamptic 
pregnancies. The expression of COX-1 mRNA does not 
differ in placentas of normal or preeclamptic pregnan-
cies, but is elevated in preeclampsia in the placental bed.44 
The TXA/PGI2 ratio, as well as that of lipid peroxides, is 
elevated in the cytotrophoblast and the stroma of placental 
villi.44 These results are in agreement with the first studies 
of prostanoids in human placenta,45 which indicate that the 
placenta, in particular the cytotrophoblast, contributes to the 
imbalance of the TXA/PGI2 ratio in preeclampsia, favoring 
platelet aggregation and the greater vascular reactivity of 
this condition.
NO
In the first trimester, eNOS is expressed in syncytiotropho-
blast, anchoring columns and the extravillous trophoblast. 
It is highly likely that NO liberated by the extravillous 
trophoblast primes the spiral arteries for their morpho-
logical transformation.46 This preconditioning is supported 
by the fact that in guinea pigs, only dilated arteries sur-
rounded by trophoblasts expressing eNOS are subsequently 
invaded.47
The expression of eNOS in human reproductive tissues 
in women with preeclampsia is discordant. However, the 
local and systemic improvement observed with L-arginine 
supplementation in hypertensive pregnant women (reduction 
of blood pressure, uterine artery resistance, synthesis of NO) 
supports the participation of NO in the systemic and local 
adaptation of pregnancy.48–51 In addition, in   preeclampsia 
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the expression of placental arginase II – the enzyme that 
degrades arginine into ornithine – is elevated in placental 
villi, and the concentration of L-arginine is reduced in cord 
blood and in villi.52
KKS
The mRNAs that code for kallikrein and the B2R are 
expressed in syncytiotrophoblast, cytotrophoblast, villous 
fetal endothelium, decidual cells of the basal and chorionic 
plate, and in intravascular and extravillous trophoblast. 
Kallikrein is present in these same cell types, with the 
exception of the anchoring columns and the extravillous 
trophoblast.53,54 In placenta accreta, a condition of exag-
gerated trophoblast invasion, the expression of kallikrein is 
increased in syncytiotrophoblast, and that of the B2R in the 
fetal endothelium and the extravillous trophoblast; in contrast 
to normal pregnancy, kallikrein is expressed in extravillous 
trophoblast. The only difference observed in preeclampsia – 
the increase of the B2R in the extravillous trophoblast – has 
been interpreted as support to the formation of AT-1-R and 
B2R heterodimers.55
The B2R-induced migration and invasion in immortal-
ized extravillous trophoblasts recently described by the 
authors of this paper56 supports the role of the KKS in 
placentation.
Vasodilator components of the RAS
The functional importance of the RAS in pregnancy is high-
lighted by the catastrophic effects of converting enzyme inhibi-
tors on fetal wellbeing,57,58 by the association of preeclampsia 
to autoantibodies against the AT-1-R, and to the M235T 
polymorphism of the gene that codes for angiotensinogen,59 
and finally, by the preeclamptic syndrome presented by female 
mice previously transfected with the human angiotensinogen 
mated with males transfected with the human renin gene.60 
Ang-(1–7) and ACE2, its main generating enzyme, are 
expressed in syncytio and cytotrophoblast, villous smooth 
vascular muscle, extravillous and intraarterial trophoblast, 
decidual cells, umbilical cord endothelium, and vascular 
smooth muscle. Ang-(1–7) is no different in placental villi 
from normotensive and preeclamptic pregnancies, but Ang II is 
increased, suggesting a balance that favors vasoconstriction.61 
In preeclamptic uterine placental bed, Ang II peptide levels, 
and renin- and Ang-converting enzyme mRNA expression 
were elevated compared with normal pregnancy.62 Angio-
tensinogen and the AT-1-R are increased in villi and decidua 
of preeclampsia.61 Herse et al found an overexpression of the 
vasoconstrictor AT-1-R mRNA in the decidua of preeclamptic 
pregnancies while that of the vasodilator AT-2-R in decidua 
and placenta was exceptionally present in preeclampsia and 
prevalent in control pregnancies.31
Vasoconstriction
Angiotensinogen
Vasodilation Vasodilation Vasodilation
antiaggregation
Arachidonic
acid VEGF
L-arginine
Kininogens
B2R
Bradykinin PGH2
VEGF-R2 (Flk)
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Mas-R
Angiotensin II
Angiotensin I
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antiaggregation
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Figure 1 Interactions between the different vasodilator systems.
Note: Inhibitory pathways = arrows interrupted by oblique lines. Adapted from Valdés G, Kaufmann P, Corthorn J, Erices R, Brosnihan KB, Joyner-Grantham J. Vasodilator 
factors in the systemic and local adaptations to pregnancy. Reprod Biol Endocrinol. 2009;7:799 with permission of the publisher, BioMed Central.
Abbreviations: ACE, angiotensin converting enzyme; AT-1-R, angiotensin II type 1 receptor; AT-2-R, angiotensin II type 2 receptor; B2R, bradykinin 2 receptor; eNOS, 
endothelial nitric oxide synthase; Flk, fetal liver kinase 1; Mas-R, Mas receptor; NO, nitric oxide; PGH2, prostaglandin H2; VEGF, vascular endothelial growth factor; VEGF-R2, 
VEGF receptor 2.
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The expression of the vasodilator receptor of Ang IV, 
AT-4-R, is increased in normal term placentas and is reduced 
in preeclampsia. Placental explants incubated with Ang IV 
or Ang II show increased trophoblast invasion and reduced 
apoptosis.63
VEGF
During the menstrual cycle, VEGF, and its receptors FLT-1 
and KDR, are expressed in the endometrium.64,65 In preg-
nancy, VEGF is mainly expressed in villous cyto- and syncy-
tiotrophoblast, the invading front of the anchoring columns, 
and extravillous and endovascular trophoblast.66–68 VEGF in 
the perivascular trophoblast could prime the spiral arteries 
to invasion, and in placental villi, enhance the blood flow in 
fetal capillaries. In a dual perfusion model of term placental 
lobes, physiological concentrations of VEGF exert a potent 
vasodilator effect on vascular fetoplacental vessels, partially 
mediated by KDR-induced NO stimulation.41 Transfection of 
the VEGF gene to uterine arteries provokes vasodilatation, 
reduces the response to phenylephrine, and potentiates the 
response to bradykinin.69
The sites of expression of paracrine vasodilator factors, 
their generating enzymes, and their receptors (Figure 2) 
support their participation not only in blood flow regulation 
in fetal and maternal vessels but suggest other functions as 
well. Due to the cognate pleitropic effects of these factors,70 
they could participate in platelet aggregation and in nonva-
soactive processes such as: (1) angiogenesis, (2) interstitial 
trophoblast invasion, (3) transformation of spiral arteries, 
and (4) the replacement of their endothelium by intra-arterial 
trophoblast. However, it must be taken into account that the 
expression of vasodilator pleiotropic factors in late pregnancy 
does not represent their expression during the determinant 
first 20 weeks of pregnancy.
Hypertensive pregnancy and its 
association with late cardiovascular 
disease in women
Epidemiological studies associate preeclampsia, other 
hypertensive gestations, and diseases related to defective 
placentation to greater cardiovascular risk,71–75 so that preg-
nancy is considered a stress test to cardiovascular health. In 
addition, preeclampsia also increases the risk of end-stage 
renal disease.76
In a study performed by the authors of this paper, 
in women submitted to coronary angiography because 
of   clinical suspicion of coronary artery disease, it was 
found that women with a previous hypertensive pregnancy 
  presented a greater number of arteries with significant 
lesions according to age than women with normotensive 
gestation.77 This same study underscored the increased risk 
of a familial history of premature cardiovascular disease 
both for hypertension in pregnancy and coronary disease. 
Many are the risks shared by hypertensive pregnancy and 
  cardiovascular   disease (eg, obesity, metabolic syndrome, dia-
betes, premature cardiovascular disease, endothelial dysfunc-
tion, thrombophilias, hyperhomocistinemia,   inflammation, 
ADMA, and oxidative stress). These factors provoke the 
first stage of atheromatous disease, endothelial dysfunction, 
which has been demonstrated far from   parturition in subjects 
with prior preeclampsia,18 and especially with early onset 
preeclampsia.78 As women with recurrent miscarriages also 
present endothelial dysfunction,79 this alteration probably 
lies at the root of placentation defects and is not derived 
from the hypertensive phase of preeclampsia. It is feasible 
that the association between hypertensive pregnancies and 
Figure 2 Diagram of the uteroplacental interface, showing its main cell types and 
the vasodilator repertoire of each type.9 The discontinuous yellow line depicts the 
path of trophoblasts that detach from the anchoring column to migrate through the 
uterine stroma, destroy the vascular smooth muscle, and colonize the lumen of the 
spiral arteries.
Note:  Adapted  from  Valdés  G,  Kaufmann  P,  Corthorn  J,  Erices  R,  Brosnihan 
KB, Joyner-Grantham J. Vasodilator factors in the systemic and local adaptations 
to pregnancy. Reprod Biol Endocrinol. 2009;7:79 with permission of the publisher, 
BioMed Central.
Abbreviation: NK, natural killer.
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Second half pregnancy
Pregestational maternal
endothelium
Placental ischemia due to defective transformation of the spiral arteries
increased placental mass due to multiple and molar pregnancy. 
Cardiovascular risks (obesity, insulin resistance, diabetes,
hypertension, hyperlipidemia, homocysteinemia, ADMA, chronic infections)
Figure 3 Diagram showing the relation between the placenta and the maternal endothelium, in ischemic conditions, increased placental mass, and underlying cardiovascular 
risks. The microphotographs of the placental villi show syncytial knots prior to being deported into the maternal circulation (orange circles). In addition, the placenta sheds 
factors to the maternal circulation (green stars: sFLT-1, agonist autoantibodies to the AT-1-R, ADMA, and reactive oxygen species). Both syncytiotrophoblast microparticles 
and the soluble factors provoke endothelial dysfunction in pregestational healthy (smooth borders) or dysfunctional endothelial cells (spiky borders). Pregestational endothelial 
dysfunction also hinders uterine artery transformation (red broken arrow).
Abbreviations: ADMA, asymmetric dimethylarginine; AT-1-R, angiotensin II type 1 receptor; sFLT-1, soluble fms-like tyrosine kinase 1.
late cardiovascular disease is given by risk factors within 
high normal limits in the reproductive stage, which do not 
provide an ample margin to the metabolic, hemodynamic, 
and inflammatory changes provoked by gestation. Based 
on the hypothesis that hypertension in pregnancy expresses 
a combination of underlying maternal conditions, and the 
placental debris/factors that are shed into the maternal cir-
culation, the authors of this paper propose that proteinuric 
hypertension (preeclampsia) derives from combinations 
of placental and preexisting maternal   factors (Figure 3). 
Nonproteinuric hypertension (eg, transient hypertension or 
exacerbation of a preexistent hypertension) on the contrary 
may derive from a reduced capacity to stimulate vasodilator/
antiaggregating factors (eg, PGI2, kallikrein, and   Ang-(1–7)), 
a limitation that impinges the maternal hemodynamic 
  adaptation to pregnancy, and later favors the development 
of cardiovascular disease.
The authors of this paper cannot avoid referring to the 
lasting hemodynamic and metabolic effects exerted on the 
offspring by severe reduced perfusion of the intervillous 
space either in intrauterine or later life (alterations in the 
fetal arteries in order to preserve cerebral blood flow, intra-
uterine growth restriction, oligamnion, and spontaneous or 
induced preterm delivery). Be it by genetic determinants 
of trophoblast invasion, vasoactive adaptation, epigenetic 
changes, or intrauterine programming, the offspring will 
have a higher cardiovascular and metabolic risk,80,81 which 
needs to be addressed.
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Conclusion
The data analyzed in this review shows that normal gestation 
represents a paradigm of a finely tuned vasodilator/vasocon-
strictor balance, which is tipped to the vasoconstrictor arm, 
in preeclampsia (Figure 4). On the other hand, the multiple 
factors that determine an adequate systemic and local adapta-
tion also provide a diversity of pathways that could go awry 
and generate preeclampsia, transforming what was initially 
considered a disease into a syndrome.
Having focused on the equilibrium of vasoactive sys-
tems, we cannot disregard the morphological changes of the 
cardiovascular system induced by gestation. The high flow 
arteriovenous fistula represented by the intervillous space, 
and the increases in aortic valve area, ventricular mass,82 and 
aortic compliance83 underscore the extraordinary cardiovas-
cular plasticity demanded by pregnancy.
The authors of this paper wish to emphasize that an 
adequate or a defective adaptation to pregnancy is expressed 
in several stages. The first silent stage is determined by an 
extensive or a shallow trophoblast invasion, and is only detected 
by ultrasonographic study of uterine arteries. The second is 
expressed clinically as a normal, preeclamptic, or a hypertensive 
pregnancy depending on the amount of placental deportation 
and the conditions of the maternal vasculature. Lastly, when the 
protection provided by estrogen is lost, cardiovascular diseases 
will be absent or present depending on the underlying risks that 
influenced pregnancy and the variations induced by lifestyle. No 
wonder gestation, which is equivalent to a prolonged moderate 
exercise,82 is a powerful and lasting stress test.84
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